The
biosurgery market is a highly competitive market, with large number of players
competing for greater market penetrance and higher market shares. Some of the
major players in this market include Johnson & Johnson (U.S.), Baxter
International Inc. (U.S.), Sanofi Group (France), Covidien plc (Ireland), Cryolife,
Inc. (U.S.), Stryker Corporation (U.S.), and Getinge Group (Sweden).
Johnson
& Johnson (U.S.) led the sealants, hemostatic agents, adhesion barriers,
and staple-line reinforcement agents market in 2014. This was majorly
attributed to the company’s strong and wide product portfolio and strong
presence across the globe, covering North America, Europe, the Middle
East and Africa, and Asia-Pacific. The company strongly focuses on introducing
new products and gaining regulatory approvals for its products in different
markets. The company gained approvals for additional indications for its
existing products which strengthened its revenue generation. Moreover,
in May 2011, the company launched a new product—ETHICON
SECURESTRAP 5mm Absorbable Strap in the U.S., which widened its portfolio for
the biosurgery market. Baxter International, Inc. (U.S.) was the second leading
company for the sealants, hemostatic agents, adhesion barriers, and staple-line
reinforcement agents market in 2014.
Medtronic, Inc. (U.S.) led the bone-graft
substitutes market in 2014 owing to its strong product portfolio and
significant presence in the demineralized bone matrix (DBM) market. The other
leading players in the bone-graft substitute products market include Johnson
& Johnson (U.S.), Integra LifeSciences (U.S.), and Stryker Corporation
(U.S.).
Mergers and acquisitions, expansions,
and new product launches were the key strategies adopted by major players in the
biosurgery market from 2011 to 2015. Mergers and acquisitions was the preferred
growth strategy during the forecast period, as this strategy enabled greater
penetrance of the market through better product offerings.
No comments:
Post a Comment